Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt No Debt
ARQL's Cash to Debt is ranked higher than
96% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ARQL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ARQL' s 10-Year Cash to Debt Range
Min: 0.92  Med: 11.26 Max: No Debt
Current: No Debt
Equity to Asset 0.67
ARQL's Equity to Asset is ranked lower than
52% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARQL: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
ARQL' s 10-Year Equity to Asset Range
Min: -0.16  Med: 0.67 Max: 0.93
Current: 0.67
-0.16
0.93
F-Score: 2
Z-Score: -8.68
M-Score: -2.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -191.67
ARQL's Operating margin (%) is ranked lower than
62% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. ARQL: -191.67 )
Ranked among companies with meaningful Operating margin (%) only.
ARQL' s 10-Year Operating margin (%) Range
Min: -790.25  Med: -107.08 Max: 4.14
Current: -191.67
-790.25
4.14
Net-margin (%) -183.06
ARQL's Net-margin (%) is ranked lower than
62% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. ARQL: -183.06 )
Ranked among companies with meaningful Net-margin (%) only.
ARQL' s 10-Year Net-margin (%) Range
Min: -582.35  Med: -98.18 Max: 7.66
Current: -183.06
-582.35
7.66
ROE (%) -46.35
ARQL's ROE (%) is ranked lower than
61% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ARQL: -46.35 )
Ranked among companies with meaningful ROE (%) only.
ARQL' s 10-Year ROE (%) Range
Min: -141.91  Med: -34.73 Max: 4.84
Current: -46.35
-141.91
4.84
ROA (%) -29.00
ARQL's ROA (%) is ranked lower than
53% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ARQL: -29.00 )
Ranked among companies with meaningful ROA (%) only.
ARQL' s 10-Year ROA (%) Range
Min: -44.05  Med: -22.05 Max: 3.4
Current: -29
-44.05
3.4
ROC (Joel Greenblatt) (%) -4659.71
ARQL's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ARQL: -4659.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARQL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3704.36  Med: -241.17 Max: 14.59
Current: -4659.71
-3704.36
14.59
Revenue Growth (3Y)(%) -41.50
ARQL's Revenue Growth (3Y)(%) is ranked lower than
81% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARQL: -41.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARQL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.3  Med: 13.15 Max: 44.2
Current: -41.5
-61.3
44.2
EBITDA Growth (3Y)(%) 26.00
ARQL's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ARQL: 26.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARQL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.5  Med: 17.70 Max: 143.8
Current: 26
-45.5
143.8
EPS Growth (3Y)(%) 22.80
ARQL's EPS Growth (3Y)(%) is ranked higher than
80% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ARQL: 22.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARQL' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.4  Med: -14.90 Max: 132.1
Current: 22.8
-48.4
132.1
» ARQL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ARQL Guru Trades in Q3 2014

Jim Simons 1,120,035 sh (+1.62%)
Chuck Royce 200,000 sh (unchged)
First Eagle Investment 2,843,599 sh (unchged)
Paul Tudor Jones Sold Out
George Soros Sold Out
» More
Q4 2014

ARQL Guru Trades in Q4 2014

First Eagle Investment 4,444,899 sh (+56.31%)
First Eagle Investment 4,444,899 sh (+56.31%)
Jim Simons 1,532,767 sh (+36.85%)
Chuck Royce 200,000 sh (unchged)
» More
Q1 2015

ARQL Guru Trades in Q1 2015

First Eagle Investment 5,719,968 sh (+28.69%)
Jim Simons 1,873,783 sh (+22.25%)
Chuck Royce Sold Out
» More
2015

ARQL Guru Trades in 2015

First Eagle Investment 8,719,968 sh (+52.45%)
» More
» Details

Insider Trades

Latest Guru Trades with ARQL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Arqule Inc

Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc
Jean-Marie Eveillard recently increased his stakes in biotech company Arqule Inc (NASDAQ:ARQL), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/B 2.90
ARQL's P/B is ranked higher than
68% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ARQL: 2.90 )
Ranked among companies with meaningful P/B only.
ARQL' s 10-Year P/B Range
Min: 1.39  Med: 2.57 Max: 111.17
Current: 2.9
1.39
111.17
P/S 9.50
ARQL's P/S is ranked higher than
54% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. ARQL: 9.50 )
Ranked among companies with meaningful P/S only.
ARQL' s 10-Year P/S Range
Min: 1.93  Med: 9.22 Max: 102.75
Current: 9.5
1.93
102.75
Current Ratio 3.30
ARQL's Current Ratio is ranked lower than
59% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ARQL: 3.30 )
Ranked among companies with meaningful Current Ratio only.
ARQL' s 10-Year Current Ratio Range
Min: 1.06  Med: 3.35 Max: 12.74
Current: 3.3
1.06
12.74
Quick Ratio 3.30
ARQL's Quick Ratio is ranked lower than
56% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ARQL: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
ARQL' s 10-Year Quick Ratio Range
Min: 1.06  Med: 3.34 Max: 12.74
Current: 3.3
1.06
12.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.05
ARQL's Price/Net Cash is ranked higher than
85% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ARQL: 3.05 )
Ranked among companies with meaningful Price/Net Cash only.
ARQL' s 10-Year Price/Net Cash Range
Min: 1.47  Med: 4.04 Max: 645.83
Current: 3.05
1.47
645.83
Price/Net Current Asset Value 2.95
ARQL's Price/Net Current Asset Value is ranked higher than
83% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ARQL: 2.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARQL' s 10-Year Price/Net Current Asset Value Range
Min: 1.29  Med: 3.70 Max: 252.5
Current: 2.95
1.29
252.5
Price/Tangible Book 2.90
ARQL's Price/Tangible Book is ranked higher than
74% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ARQL: 2.90 )
Ranked among companies with meaningful Price/Tangible Book only.
ARQL' s 10-Year Price/Tangible Book Range
Min: 0.57  Med: 2.55 Max: 95.33
Current: 2.9
0.57
95.33
Price/Median PS Value 1.03
ARQL's Price/Median PS Value is ranked higher than
56% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. ARQL: 1.03 )
Ranked among companies with meaningful Price/Median PS Value only.
ARQL' s 10-Year Price/Median PS Value Range
Min: 0.09  Med: 0.83 Max: 8.76
Current: 1.03
0.09
8.76
Earnings Yield (Greenblatt) (%) -39.50
ARQL's Earnings Yield (Greenblatt) (%) is ranked lower than
88% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ARQL: -39.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARQL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -230.1  Med: 0.00 Max: 0
Current: -39.5
-230.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AQL.Germany,
Arqule Inc was organized as a Delaware corporation in 1993 in Delaware. The Company is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. It employ technologies such as its ArQule Kinase Inhibitor Platform ("AKIPTM") to design and develop drugs that have the potential to fulfill this mission. Its product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. Its product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase. C-Met is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. The Company and its partners, Daiichi Sankyo Co., Ltd. ('Daiichi Sankyo') and Kyowa Hakko Kirin Co., Ltd. ('Kyowa Hakko Kirin'), are implementing a clinical development program designed to realize the broad potential of tivantinib as a well-tolerated single agent and in combination with other anti-cancer therapies in a number of disease indications The Company has licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin. Its proprietary pipeline is directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers. The advanced candidates in this pipeline are ARQ 087, an inhibitor of fibroblast growth factor receptor, ARQ 621, an inhibitor of the Eg5 kinesin motor protein, and ARQ 736, an inhibitor of the RAF kinases, all of which are in Phase 1 clinical testing. Its drug discovery efforts are engaged mainly on AKIP, which it is using to generate compounds designed to inhibit kinases without competing with adenosine triphosphate ('ATP') for binding to the target kinase, as well as other types of kinase inhibitors. ATP is a chemical found in all living cells and is the energy source involved in a variety of physiological processes. The Company faces competition from pharmaceutical companies, biotechnology companies and academic and research organizations. The Company's product candidates, as well as the activities associated with their research, development and commercialization, are subject to extensive regulation by the FDA in the United States and by comparable authorities in other countries.
» More Articles for ARQL

Headlines

Articles On GuruFocus.com
Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
comment on ARQL Nov 29 2012 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on ARQL May 01 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Reports Second Quarter 2009 Financial Results Aug 06 2009 

More From Other Websites
ArQule to Report Second Quarter 2015 Financial Results on August 5, 2015 Jul 29 2015
ArQule to Report Second Quarter 2015 Financial Results on August 5, 2015 Jul 29 2015
ArQule Reports Interim Data from Colorectal Cancer Study - Analyst Blog Jul 07 2015
ArQule Announces Interim Phase 2 Study Results for Tivantinib in Combination with Cetuximab in... Jul 06 2015
ArQule Announces Interim Phase 2 Study Results for Tivantinib in Combination with Cetuximab in... Jul 06 2015
ARQULE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jun 01 2015
ArQule Appoints Robert J. Weiskopf as Chief Financial Officer Jun 01 2015
ArQule Appoints Robert J. Weiskopf as Chief Financial Officer Jun 01 2015
ArQule Announces Data Presentations with Tivantinib and ARQ 087 to Be Featured at ASCO 2015 May 29 2015
ArQule Announces Data Presentations with Tivantinib and ARQ 087 to Be Featured at ASCO 2015 May 29 2015
ArQule, Inc. to Present at Jefferies 2015 Global Healthcare Conference May 27 2015
ArQule, Inc. to Present at Jefferies 2015 Global Healthcare Conference May 27 2015
ARQULE INC Financials May 15 2015
ARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 13 2015
10-Q for ArQule, Inc. May 08 2015
ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... May 07 2015
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 06 2015
ArQule Reports First Quarter 2015 Financial Results May 06 2015
ArQule reports 1Q loss May 06 2015
ArQule reports 1Q loss May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK